Movasin

Movasin – the selection TsOG-2 inhibitor, non-steroidal anti-inflammatory drug (NPVS).

Form of release and structure

• Tablets: a ploskotsilindrichesky form, round, light yellow color (on a surface the small mramornost of coloring), with a facet (in blister strip packagings can be noted 10 pieces, 1 or 2 packagings in a cardboard pack);
• Solution for intramuscular introduction (in oil): transparent (can be slightly opalescent), color, yellow with a greenish shade (in glass ampoules on 1,5 ml, 3 or 5 ampoules in blister strip packagings, 1 packaging in a cardboard pack).

Active ingredient – to meloksika:

• 1 tablet – 7,5 or 15 mg;
• 1 ampoule of solution – 15 mg.

Excipients of tablets: povidone 12 600, кросповидон (коллидон CL-M), microcrystallic cellulose, potato starch, lactoses monohydrate, magnesium stearate, talc.

Additional substances of solution: sodium chloride, Megluminum, glycine, glycofurfural, sodium chloride, sodium hydroxide, half-oxameasures 188, water for injections.

Indications to use

Movasin – drug for symptomatic therapy of the following diseases of a musculoskeletal system:

• Pseudorheumatism;
• Osteoarthrosis;
• Bekhterev's disease (ankylosing spondylitis).

Contraindications

Strict:

• Children's age up to 12 years – for tablets, up to 18 years – for solution for introduction in oil;
• Period of pregnancy and lactation;
• Chronic renal failure at the patients who are not exposed to dialysis (clearance of creatinine less than 30 ml/minute), the progressing diseases of kidneys (including the confirmed hyperpotassemia);
• The expressed liver failure, active disease of a liver;
• Full or incomplete combination of bronchial asthma, the nose recuring a polypose of a mucous membrane / околоносовых bosoms and intolerance of non-steroidal anti-inflammatory drugs, including acetylsalicylic acid (in the anamnesis including);
• Cerebrovascular or other bleeding;
• Inflammatory diseases of intestines (for example, ulcer colitis or disease Krone);
• Active gastrointestinal bleeding, erosive cankers of a mucous membrane of a stomach or 12-perstny gut;
• Dekompensirovanny heart failure;
• State after performing aortocoronary shunting;
• Deficit of lactase, intolerance of a galactose, glyukozo-galaktozny malabsorption;
• Hypersensitivity to drug components.

In the following cases Movasin it is necessary to apply with care:

• The accompanying therapy by one of the following drugs: selective serotonin reuptake inhibitors (including sertraline, fluoxetine, to tsitalopra, пароксетин), antiagregant (including acetylsalicylic acid also klopidogret), anticoagulants, peroral glucocorticosteroids;
• Prolonged use of NPVS;
• Advanced age;
• Smoking;
• Frequent alcohol intake;
• Heavy somatopathies;
• Dislipidemiya or lipidemia;
• Existence of an infection of Helicobacter pylori;
• Anamnestic data on a digestive tract canker;
• Clearance of creatinine of 30-60 ml/minute;
• Heart failure in compensation stage;
• Cerebrovascular diseases;
• Diseases of peripheral arteries;
• Coronary heart disease;
• Diabetes mellitus.

Route of administration and dosage

Tablets
Movasin in tablets it is necessary to accept in 1 times a day during food.

The recommended doses:

• Ankylosing spondylarthritis: on 15 mg a day;
• Pseudorheumatism: on 15 mg a day, if necessary a dose reduce to 7,5 mg;
• Osteoarthrosis: on 7,5 mg a day, in case of insufficiency of therapeutic effect the dose is increased to 15 mg.

The highest resolved daily dose – 15 mg, for patients with a renal failure on a hemodialysis and patients with the increased risk of development of undesirable effects – 7,5 mg.

Solution for intramuscular introduction
Movasin in the form of solution for introduction in oil enter deeply into a muscle of 1 times a day.

Depending on weight of inflammatory process and expressiveness of a pain syndrome the dose makes 7,5 or 15 mg.

The highest resolved daily dose – 15 mg, for patients with small and moderate functional disturbances of kidneys (clearance of creatinine more than 30 ml/minute), patients with a terminal renal failure on a hemodialysis and persons with the increased risk of development of undesirable effects – 7,5 mg.

Drug in oil is used by only the first 2-3 days. In need of treatment continuation to the patient appoint tablets Movasin.

At a combination of different dosage forms of drug it is necessary to consider that the total daily dose of a meloksikam should not exceed 15 mg.

Side effects

• From the alimentary system: often (more than 1% of cases) – dispepsichesky frustration (nausea, abdominal pains, a meteorism, lock/diarrhea, vomiting); infrequently (0,1-1% of cases) – stomatitis, an eructation, a hyperbilirubinemia, an esophagitis, passing increase in activity of hepatic transaminases, bleeding from digestive tract (including hidden), an ulcer in a gastroduodenal zone; seldom (less than 0,1% of cases) – perforation of digestive tract, colitis, gastritis, hepatitis;
• From an urinary system: infrequently – increase in urea in blood serum and/or a giperkreatininemiya; seldom – an acute renal failure; separate cases (communication using a meloksikam is not proved) – a hamaturia, an albuminuria, intersticial nephrite;
• From cardiovascular system: often – peripheral hypostases; infrequently – rushes of blood to face skin, increase in arterial pressure, heartbeat;
• From bodies of a hemopoiesis: often – decrease in concentration of hemoglobin in blood; infrequently – change of a blood count, including thrombocytopenia, a leukopenia;
• From integuments: often – an itch and rash on skin; infrequently – a small tortoiseshell; seldom – a mnogoformny erythema, a toxic epidermal necrolysis, violent rashes, a photosensitization;
• From sense bodys: seldom – conjunctivitis, a vision disorder (including an illegibility of visual perception);
• From respiratory system: seldom – a bronchospasm;
• From a nervous system: often – a headache; infrequently – a sonitus, drowsiness, вертиго; seldom – confusion of consciousness, unstable mood, a disorientation;
• Local reactions at intramuscular introduction: often – puffiness; seldom – morbidity in the place of an injection;
• Allergic reactions: seldom – a Quincke's disease, anaphylactic/anaphylactoid reactions.

Special instructions

With care it is necessary to apply Movasin at the elderly people sick with cirrhosis, chronic heart failure with the phenomena of a circulatory unefficiency and patients with the hypovolemia which appeared owing to surgical intervention. During treatment it is necessary to control indicators of function of kidneys.

To reduce risk of development of side effects from the alimentary system, it is recommended to apply the smallest effective dose during minimum possible short course.

Intravenous administration of solution Movasin is forbidden!

The patients receiving to meloksika along with diuretic drugs have to accept enough liquid.

As well as all NPVS, Movasin can mask symptoms of infectious diseases.

Drug can cause drowsiness, a headache and dizziness therefore for therapy it is worth refusing driving of the car and occupations types of activity with potentially dangerous effects (which require special attention).

Medicinal interaction

• Other NPVS, including acetylsalicylic acid: the risk of formation of erosive cankers and bleedings of digestive tract increases;
• Selective serotonin reuptake inhibitors: the probability of development of bleeding from digestive tract increases;
• Anti-hypertensive drugs: their efficiency decreases;
• Lithium drugs: lithium cumulation develops, its toxic action (in need of use of such combination it is necessary to control lithium level in blood) increases;
• Methotrexate: the risk of development of a leukopenia and anemia, toxic impact on a hemopoiesis increases (it is necessary to do periodically the general blood test);
• Diuretics, cyclosporine: the risk of development of a renal failure increases;
• Colestyraminum: removal of a meloksikam through digestive tract increases;
• Anticoagulants (including warfarin, heparin, тиклопидин), thrombolytic drugs (including Streptokinasa, fibrinolysin): the risk of development of bleedings (at use of a similar combination it is necessary to control indicators of system of coagulability of blood) increases;
• Intrauterine contraceptive means: their efficiency decreases.

Terms and storage conditions

To store in the dry and protected from light place unavailable to children, at a temperature: tablets – no more than 25 ºС, solution for intramuscular introduction – no more than 30 ºС.

Period of validity – 3 years.